Geron Corporation
NASDAQ:GERNBiotechnology
Healthcare
$0.91 +4.07%
+$0.05 today
- Market cap
- $588.19M
- Beta
- 0.60
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.10
52W Low $1.04High $2.01
Volume 19.64M
Average 16.28M
Income Statement
Follow revenue through to earnings.
Revenue
$183.88M
FY 2025 · Annual
+138.8% YoYOperating Income
-$53.84M
FY 2025 · Annual
Net Income
-$85.78M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.39M | 596K | 237K | 76.99M | 183.88M |
| Cost of Revenue | 0 | 0 | 0 | 1.26M | 4.75M |
| Gross Profit | 1.39M | 596K | 237K | 75.74M | 179.14M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 98.4% | 97.4% |
| Research & Development | 85.73M | 95.52M | 125.05M | 103.74M | 73.72M |
| Selling, General & Admin | 29.67M | 43.63M | 69.14M | 145.73M | 159.26M |
| Operating Expenses | 115.39M | 139.15M | 194.18M | 249.47M | 232.97M |
| Depreciation & Amortization | 783K | 868K | 1.03M | 1.22M | 1.2M |
| EBITDA | (111.59M) | (134.15M) | (174.78M) | (154.85M) | (51.92M) |
| EBITDA Margin | -8010.7% | -22508.6% | -73747.7% | -201.1% | -28.2% |
| Operating Income | (114M) | (138.55M) | (193.94M) | (173.73M) | (53.84M) |
| Operating Margin | -8183.7% | -23246.6% | -81832.9% | -225.6% | -29.3% |
| Interest Income | 527K | 2.53M | 18.15M | 19.61M | 18.12M |
| Interest Expense | 3.74M | 6.88M | 8.31M | 18.5M | 32.66M |
| Other Income / Expenses | (2.11M) | (3.35M) | 9.82M | (840K) | (31.95M) |
| Income Before Tax | (116.11M) | (141.9M) | (184.13M) | (174.57M) | (85.78M) |
| Pre-Tax Margin | -8335.4% | -23808.9% | -77690.7% | -226.7% | -46.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (116.11M) | (141.9M) | (184.13M) | (174.57M) | (85.78M) |
| Net Margin | -8335.4% | -23808.9% | -77690.7% | -226.7% | -46.7% |
| EPS (Basic) | (0.37) | (0.37) | (0.32) | (0.27) | (0.13) |
| EPS (Diluted) | (0.37) | (0.37) | (0.32) | (0.27) | (0.13) |
| 327.63M | 380.78M | 570.65M | 646.03M | 666.66M | |
| 327.63M | 380.78M | 570.65M | 646.03M | 666.66M |
GERN Earnings Waterfall · TTM
NASDAQ:GERN · Revenue to Net Income
Key Ratios
EPS$-0.10
Gross Margin86.2%
Net Margin-36.1%
P/E Ratio-25.6
P/S Ratio19.0
Analysis
$196.1M of revenue converted into -$69.6M of net income for the selected period. Gross margin is 86.2% and net margin is -36.1%, showing how much revenue survives after costs and taxes. EPS is $-0.10, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Oct 28, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 1, 2026 |
How much revenue does GERN generate?
Geron Corporation (GERN) reported $183.88M of revenue in fiscal 2025.
Is GERN profitable?
Geron Corporation (GERN) reported -$85.78M of net income, with a net margin of -46.7%.
Continue the stock analysis
Jump to another research area for this company.